immunitoAI, a biotech startup that is developing an artificial intelligence (AI)-based antibody discovery and screening platform, announced that it has raised $1 million in a seed round, as reported YourStory.
The funds raised will be used for product development and industry partnerships.
CEO Aridni Shah said that "our vision is to make antibody therapy a norm with the help of our technology. We plan on using this seed funding to develop our AI products and validate the predictions through biological experiments."
The focus is on antibody screening and improvement in the short term, but the startup plans to develop their own antibody candidates in the mid and long term.
To read more NewsPoints articles, click here.